GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs), today announced that it has been added to the Russell 3000® Index, following the annual Russell indexes reconstitution, effective after the market open on June 29, according to a final list of additions posted on June 26.
Annual Russell indexes reconstitution captures the 4,000 largest US stocks, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
Vered Caplan, CEO of Orgenesis, commented, “We’re pleased to be included in the Russell 3000® Index. We believe this inclusion will help improve the Company’s exposure within the global investment community. The addition to the Russell 3000® Index reflects our commitment to building shareholder value through growth of our global CGT Biotech Platform and building our pipeline of POCare Therapeutics and Technologies, with an ultimate goal of providing life-changing treatments at reduced costs within the point-of-care setting.”
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.